Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 7/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GUCY1A1 | Q02108 | 3/20 | 0.39 |
| ▸ | GUCY1B1 | Q02153 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878097 | 0.91 | ADORA3 (0.53) | ADORA3KCNH2HTR3AATMPDE5A | |
| SCHEMBL6068600 | 0.89 | CFD (0.49) | ADORA3KCNH2AURKAPDPK1RPS6KB1 | |
| SCHEMBL326724 | 0.88 | ADORA3 (0.41) | ADORA3KCNH2AURKAPDPK1RPS6KB1 | |
| SCHEMBL6223849 | 0.84 | ADORA3 (0.42) | ADORA3KCNH2AURKAPDPK1RPS6KB1 | |
| Hydrochloric Acid SCHEMBL6068508 | 0.83 | ADORA3 (0.42) | ADORA3KCNH2AURKAPDPK1RPS6KB1 | |
| Acetic Acid SCHEMBL16245022 | 0.83 | ADORA3 (0.45) | ADORA3KCNH2AURKAPDPK1RPS6KB1 | |
| SCHEMBL2878454 | 0.82 | PDE5A (0.40) | ADORA3KCNH2AURKAPDPK1RPS6KB1 | |
| SCHEMBL2878455 | 0.82 | PDE5A (0.40) | ADORA3KCNH2AURKAPDPK1RPS6KB1 | |
| SCHEMBL8221670 | 0.82 | PDE5A (0.40) | ADORA3KCNH2AURKAPDPK1RPS6KB1 | |
| SCHEMBL2878457 | 0.82 | L3MBTL1 (0.39) | ADORA3KCNH2AURKAPDPK1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3538520-A2 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | ADORA3 1006/4885KCNH2 3135/4885AURKA 4737/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | ADORA3 1072/4885KCNH2 3222/4885AURKA 4738/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | ADORA3 1072/4885KCNH2 3222/4885AURKA 4738/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | ADORA3 1006/4885KCNH2 3135/4885AURKA 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.